Inomax

Nitric Oxide, the active ingredient in Inomax, is a vasodilator presented as a medical gas for endotracheopulmonary use. It is employed to manage neonatal respiratory failure, persistent pulmonary hypertension of the newborn, and acute pulmonary hypertension in adults. GNH USA supplies Inomax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Inomax acts on the pulmonary vascular system to lower resistance and improve oxygenation in specific respiratory conditions.

Neonatal respiratory failure: improves oxygen exchange by reducing pulmonary vascular resistance. Persistent pulmonary hypertension of the newborn: provides selective pulmonary vasodilation to support transition to normal circulation. Acute pulmonary hypertension in adults: lowers pulmonary arterial pressure and enhances right‑ventricular function.

Inomax may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects: - Transient hypotension - Methemoglobinemia (mild) - Rebound pulmonary hypertension after abrupt discontinuation - Headache or facial flushing - Nausea or vomiting

Serious or Rare Side Effects: - Severe hypotension leading to organ hypoperfusion - High‑grade methemoglobinemia requiring intervention - Pulmonary edema - Significant bleeding in patients on anticoagulants - Allergic or anaphylactoid reactions

When using Inomax, clinicians should observe specific safety measures. - Blood pressure monitoring: check systemic and pulmonary pressures regularly. - Methemoglobin levels: measure to detect accumulation, especially with prolonged use. - Hemolytic disease: avoid or use with caution in patients with severe hemolysis. - Anemia: assess hemoglobin and avoid in severe cases. - Concurrent inhaled NO therapies: adjust dose to prevent excess vasodilation. - Store at ambient temperature: keep cylinders in original packaging, protect from heat and direct sunlight.

Inomax can interact with other agents that affect vascular tone or hemoglobin.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil) – risk of profound hypotension. - Other nitric oxide donors – additive vasodilatory effect. - Nitroglycerin – excessive systemic blood pressure drop. - Methylene blue – may antagonize nitric oxide effect. - Inhaled anesthetics that potentiate vasodilation.

Moderate Interactions (Monitor Closely): - Anticoagulants – increased bleeding risk. - High‑concentration oxygen therapy – may affect NO metabolism. - Certain antibiotics (e.g., sulfonamides) – potential oxidative stress. - Other pulmonary vasodilators – cumulative effect on pulmonary pressure. - Drugs influencing hemoglobin affinity – monitor methemoglobin formation.